Lindsay Cameron
Research scientist and coauthor in psychedelic pharmacology/psychoplastogen research (affiliation not confidently verified)
Data updated
Papers
Trials
Research Footprint
Lindsay Cameron appears in 11 tracked papers (2018–2025), most studied alongside Psilocybin, DMT and Ibogaine, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).
Most-cited paper: Psychedelics promote structural and functional neural plasticity (1134 citations).
Frequent co-authors: David Olson, John McCorvy and Maxemiliano Vargas.
Background & Research
Lindsay P. Cameron appears as a coauthor on multiple psychedelic neuroscience papers centered on receptor pharmacology, behavioral effects in rodents, and the search for non-hallucinogenic compounds with therapeutic potential. The name is most strongly associated with the University of California, Davis publication record, but I could not confidently verify a current individual faculty/lab profile from the available search results.
Key Impact
Cameron is a recurring author on influential preclinical psychedelic studies, including work on psilocybin, DMT, non-hallucinogenic analogues, and 5-HT2A mechanisms.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Lindsay Cameron is associated with.